Monday, January 7, 2008

More to Come? Benitec Halted on the Australian Exchange

In what cannot be described as anything short of an amazing day for the Business of RNA(i) Therapeutics, Benitec has just announced their request to halt trading of their shares: http://www.asx.com.au/asxpdf/20080108/pdf/316tqqh1t4xm4g.pdf

This comes on the back of an Stock Exchange enquiry about irregular trading associated with rumours last week that Pfizer was interested in Tacere (as it turns out, rumours are true sometimes). As the Tacere news was already out before today's trading session, it will be interesting to see whether the trading halt request is linked to and possibly an extension of the Pfizer deal.

Update: Benitec confirmed Tacere-Pfizer news and is currently up by more than 100%. An interesting interview last year with Benitec CEO MacLeman about the possibility of Pfizer coming back to take a therapeutic DNA-directed RNAi license from Benitec in the wake of taking a research license can be found on the following website (listen carefully):

http://www.brr.com.au/event/17735

No comments:

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.